Black Diamond Therapeutics(BDTX) - 2023 Q1 - Quarterly Report

• the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators; • the extent of any required post-marketing approval commitments to applicable regulatory authorities; • development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; General and administrative Other income was $0.7 million for the three mon ...